BioDelivery Sciences Investors Have Been Burned, But Inflection Point Could Be Coming

Loading...
Loading...
  • The share price of BioDelivery Sciences International, Inc. BDSI has increased 15.01 percent over the last five trading days.
  • Roth Capital’s Scott R. Henry has maintained a Buy rating on the company, with a price target of $14.
  • Henry believes that an inflection point could be imminent, following the recent signing of a two-year contract with Tennessee Medicaid, which makes Bunavail the preferred treatment for opioid dependence.

Analyst Scott Henry explained that “Bunavail (buprenorphine/naloxone) is a buccal film for the treatment of opioid addiction. It has potential benefits over comparable treatments, including a lower rate of constipation side effects.”

Tennessee is the largest Medicaid state for buprenorphine/naloxone treatment of opioid dependence. The recently signed contract between Tennessee Medicaid and BioDelivery Sciences came into effect on October 1, making Bunavail “the only preferred buprenorphine/ naloxone treatment for opioid dependence on the preferred drug list.”

See Also: Endo Pharmaceuticals, BioDelivery Sciences Present Promising Data On New Chronic Pain Management Product

With regard to the weekly data on the drug’s performance, the number of total prescriptions fell to 1,415 in the week of September 28, as compared to 1,477 total prescriptions for the previous week.

Bunavail’s market share declined marginally from 1.01 percent in the week of September 21 to 0.97 percent in the week of September 28. However, Henry views the weekly results as neutral, given the “currently modest expectations.”

The drug is expected to garner one percent market share by January 2016, increasing to 2 percent by November 2016.

Loading...
Loading...
Posted In: Analyst ColorHealth CareReiterationAnalyst RatingsGeneralRoth CapitalScott R. Henry
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...